Pharmacological dose of vitamin B12 Is as effective as low-dose folinic acid in correcting hyperhomocysteinemia of hemodialysis patients

Renal Failure

Volumn 31, Issue 4, 2009, Pages 278-283

  Chiu, Yi Wen ^a   Chang, Jer Ming ^a,b   Hwang, Shang Jyh ^a   Tsai, Jer Chia ^a,c   Chen, Hung Chun ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Folinic acid; Hemodialysis; Hyperhomocysteinemia; Vitamin B12

Indexed keywords

FOLIC ACID; FOLINIC ACID; HOMOCYSTEINE; HYDROXOCOBALAMIN;

AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERHOMOCYSTEINEMIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERHOMOCYSTEINEMIA; LEUCOVORIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; VITAMIN B 12; VITAMIN B COMPLEX;

EID: 67651155839     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220902780010     Document Type: Article

References (30)

1. Robinson K, Gupta A, Dennis V, et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996;94:2743-2748.
2. Bostom AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int. 1997;52:10-20.
3. van Guldener C. Why is homocysteine elevated in renal failure and what can be expected from homocysteine-lowering? Nephrol Dial Transplant. 2006;21:1161-1166.
4. Bostom AG, Culleton BF. Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol. 1999;10:891-900.
5. Tremblay R, Bonnardeaux A, Geadah D, et al. Hyperhomocysteinemia in hemodialysis patients: Effects of 12-month supplementation with hydrosoluble vitamins. Kidney Int. 2000;58:851-858.
6. Sunder-Plassmann G, Fodinger M, Buchmayer H, et al. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: Results of the Vienna multicenter study. J Am Soc Nephrol. 2000;11:1106-1116.
7. Manns B, Hyndman E, Burgess E, et al. Oral vitamin B(12) and high-dose folic acid in hemodialysis patients with hyperhomocyst(e)inemia. Kidney Int. 2001;59:1103-1109.
8. Spence JD, Cordy P, Kortas C, Freeman D. Effect of usual doses of folate supplementation on elevated plasma homocyst(e)ine in hemodialysis patients: No difference between 1 and 5 mg daily. Am J Nephrol. 1999;19: 4405-4410.
9. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomized trials. BMJ 1998; 316:894-898.
10. Homocysteine Lowering Trialists' Collaboration. Dosedependent effects of folic acid on blood concentrations of homocysteine: A meta-analysis of the randomized trials. Am J Clin Nutr. 2005;82:806-812.
11. Hoffer LJ. Testing the homocysteine hypothesis in end-stage renal disease: Problems and a possible solution. Kidney Int. 2006;69:1507-1510.
12. Kaplan LN, Mamer OA, Hoffer LJ. Parenteral vitamin B12 reduces hyperhomocysteinemia in end-stage renal disease. Clin Invest Med. 2001;24:5-11.
13. Elian KM, Hoffer LJ. Hydroxocobalamin reduces hyperhomocysteinemia in end-stage renal disease. Metabolism 2002;51:881-886.
14. Hoffer LJ, Djahangirian O, Bourgouin PE, Eid J, Saboohi F. Comparative effects of hydroxocobalamin and cyanocobal-amin on plasma homocysteine concentrations in end-stage renal disease. Metabolism 2005;54:1362-1367.
15. Hoffer LJ, Saboohi F, Golden M, Barre PE. Cobalamin dose regimen for maximum homocysteine reduction in end-stage renal disease. Metabolism 2005;54:835-840.
16. Hoffer LJ, Elian KM. Parenteral vitamin B12 therapy of hyperhomocysteinemia in end-stage renal disease. Clin Invest Med. 2004;27:10-13.
17. Henning BF, Zidek W, Riezler R, Graefe U, Tepel M. Homocyst(e)ine metabolism in hemodialysis patients treated with vitamins B6, B12, and folate. Res Exp Med. 2001;200:155-168.
18. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: A common mutation in methyle-netetrahydrofolate reductase. Nat Genet. 1995;10:111-113.
19. Tsai JC, Kuo HT, Chiu YW, et al. Correlation of plasma homocysteine level with arterial stiffness and pulse pressure in hemodialysis patients. Atherosclerosis 2005;182:121-127.
20. Massy ZA. Reversal of hyperhomocyst(e)inaemia in chronic renal failure - is folic or folinic acid the answer? Nephrol Dial Transplant. 1999;14:2810-2812.
21. Bostom AG, Nadeau MR, Jacques PF, et al. Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis 1996;123:193-202.
22. Sombolos K, Papaioannou A, Christidou F, et al. The effect of two different doses comprising the simultaneous administration of intravenous B-complex vitamins and oral folic acid on serum homocysteine levels in hemodialysis patients. Int Urol Nephrol. 2006;38:725-730.
23. Koyama K, Usami T, Takeuchi O, Morozumi K, Kimura G. Efficacy of methylcobalamin on lowering total homocys-teine plasma concentrations in haemodialysis patients receiving high-dose folic acid supplementation. Nephrol Dial Transplant. 2002;17:916-922.
24. Lin BF, Yeh WT, Pan WH. The folate status in Taiwanese population from the NAHSIT 1993-1996. Nutr Sci J. 1999;24:99-117.
25. Chen KJ, Pan WH, Shaw NS, Huang RF, Lin BF. Association between dietary folate-rich food intake and folate status of elderly Taiwanese. Asia Pac J Clin Nutr. 2005; 14:244-249.
26. Arnadottir M, Hultberg B. The effect of vitamin B12 on total plasma homocysteine concentration in folate-replete hemodialysis patients. Clin Nephrol. 2003;59:186-189.
27. Sombolos K, Fragia T, Natse T, et al. The effect of long-term intravenous high dose B-complex vitamins with or without folic acid on serum homocysteine in hemodialysis patients. J Nephrol. 2002;15:671-675.
28. Jamison RL, Hartigan P, Kaufman JS, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: A randomized controlled trial. 2007;298: 1163-1170.
29. Mann JF, Sheridan P, McQueen MJ, et al. Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease - results of the renal Hope-2 study. Nephrol Dial Transplant. 2008:23:645-653.
30. Zoccali C, Mallamaci F, Tripepi G. It is important to lower homocysteine in dialysis patients. Semin Dial. 2007;20: 530-533.